Zhang Minpu, Liu Cun, Li Ye, Li Huayao, Zhang Wenfeng, Liu Jingyang, Wang Liquan, Sun Changgang
College of First Clinical Medicine, Shandong University of Traditional Chinese Medicine, Jinan, China.
College of Traditional Chinese Medicine, Weifang Medical University, Weifang, China.
Front Cell Dev Biol. 2024 Jan 9;11:1332205. doi: 10.3389/fcell.2023.1332205. eCollection 2023.
Galectin-9 (Gal-9) is a vital member of the galectin family, functioning as a multi-subtype galactose lectin with diverse biological roles. Recent research has revealed that Gal-9's interaction with tumors is an independent factor that influences tumor progression. Furthermore, Gal-9 in the immune microenvironment cross-talks with tumor-associated immune cells, informing the clarification of Gal-9's identity as an immune checkpoint. A thorough investigation into Gal-9's role in various cancer types and its interaction with the immune microenvironment could yield novel strategies for subsequent targeted immunotherapy. This review focuses on the latest advances in understanding the direct and indirect cross-talk between Gal-9 and hematologic malignancies, in addition to solid tumors. In addition, we discuss the prospects of Gal-9 in tumor immunotherapy, including its cross-talk with the ligand TIM-3 and its potential in immune-combination therapy.
半乳糖凝集素-9（Gal-9）是半乳糖凝集素家族的重要成员，作为一种具有多种生物学作用的多亚型半乳糖凝集素发挥功能。最近的研究表明，Gal-9与肿瘤的相互作用是影响肿瘤进展的一个独立因素。此外，免疫微环境中的Gal-9与肿瘤相关免疫细胞相互作用，这为阐明Gal-9作为免疫检查点的身份提供了依据。深入研究Gal-9在各种癌症类型中的作用及其与免疫微环境的相互作用，可能会产生后续靶向免疫治疗的新策略。本综述重点关注了在理解Gal-9与血液系统恶性肿瘤以及实体瘤之间直接和间接相互作用方面的最新进展。此外，我们还讨论了Gal-9在肿瘤免疫治疗中的前景，包括其与配体TIM-3的相互作用及其在免疫联合治疗中的潜力。
